In both cases, the effective protection of human subjects should receive much higher priority, thereby justifying the modest added expense, which probably would amount to no more than 1-2% of the overall cost of clinical studies. If such research is truly to serve the public good, the safety, health, and dignity of human subjects should not be compromised.
在以上两个情况中，有效保护人体研究对象应当得到更大的优先，从而为有限增加费用提供理由。这些增加可能会令临床研究的总体费用增加不到1-2％。如果这样的研究的确是服务于公共利益，那么，就不应当损害人体研究对象的安全、健康以及尊严。